TrialSchizophrenia bulletin2014

A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

George M Haig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.